NEW INDICATIONS

Keytruda Now FDA Approved for Adjuvant Treatment of Renal-Cell Carcinoma

JHOP - December 2021 Vol 11, No 6 - FDA Oncology Update
Download PDF

On November 17, 2021, the FDA accelerated the approval of a new indication for pembrolizumab (Keytruda; Merck), for the adjuvant treatment of patients with renal-cell carcinoma (RCC) at intermediate-high or high risk for recurrence after nephrectomy or after nephrectomy and resection of metastatic lesions.

This approval was evaluated in the KEYNOTE-564 study, a multicenter, randomized, double-blind, placebo-controlled clinical trial of 994 patients with RCC at intermediate-high or high risk for recurrence, or for patients with no evidence of disease. The patients were randomized in a 1:1 ratio to pembrolizumab every 3 weeks or to placebo for up to 1 year, until disease recurrence or unacceptable adverse events.

The primary end point was investigator-assessed disease-free survival (DFS), defined as time to recurrence, metastasis, or death. The overall survival (OS) was a secondary end point. At a prespecified interim analysis, significant improvement in DFS was demonstrated, including 109 (22%) DFS events in the pembrolizumab arm and 151 (30%) DFS events in patients receiving placebo (hazard ratio, 0.68; 95% confidence interval, 0.53-0.87; P = .0010). The median DFS was not reached in either arm. At the time of the analysis, OS data were not mature, and 5% of deaths were reported in the overall population.

The most common (≥20%) adverse reactions to pembrolizumab in this study were musculoskeletal pain, fatigue, rash, diarrhea, pruritus, and hypothyroidism.

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: